ORIGINAL PAPER
Serum levels of salusin β in acute lymphoblastic leukaemia and Wilms’ tumour survivors – preliminary report
1
Department of Paediatrics, Haematology and Oncology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
2
Department of Paediatrics, Haematology and Oncology, University Clinical Centre, Gdansk, Poland
3
Faculty of Health Sciences with Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Gdansk, Poland
4
Department of Clinical Nutrition and Dietetics, Faculty of Health Sciences with Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Gdansk, Poland
Submission date: 2022-03-30
Final revision date: 2022-05-29
Acceptance date: 2022-05-31
Publication date: 2022-12-30
Pediatr Pol 2022;97(4):290-295
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Cardiovascular diseases (CVD) are one of the long-term side effects of childhood cancer treatment. Salusin β is an indicator of atherosclerosis development. The aim of the study was to evaluate serum salusin β levels in long-term acute lymphoblastic leukaemia survivors (ALLs) and Wilms’ tumour survivors (WTs) and compare these levels to established CVD risk factors.
Material and methods:
Thirty-seven ALLs and eleven WTs underwent physical examination and laboratory tests after an overnight fast at least 5 years after the end of oncological treatment. The laboratory tests included analysis of lipid profiles, serum glucose levels, renal parameters and salusin β levels.
Results:
The groups did not vary in age, time from the end of the treatment, number of obese persons, blood pressure, lipid profile, serum creatinine and glucose levels. The ALLs had greater weights and greater waist circumferences. The serum cystatin level was higher and the cystatin-based estimated glomerular filtration rate was lower in the WTs. Salusin β was higher in the WT group, but the result was not statistically significant.
Conclusions:
Acute lymphoblastic leukaemia survivors and WTs differ in terms of types of long-term side effects. Acute lymphoblastic leukaemia survivors more often develop obesity and metabolic problems, whereas WTs tend to develop renal disorders. Salusin β levels are associated with the level of LDL in ALLs and can indicate lipid disorders in patients with higher risk of obesity, suggesting that it could be a predictor of atherosclerosis. Further investigations are necessary to confirm this result. It is necessary to continue follow-up among adults who have been treated for childhood cancers to reveal long-term side effects such as cardiovascular disorders.
Cardiovascular diseases (CVD) are one of the long-term side effects of childhood cancer treatment. Salusin β is an indicator of atherosclerosis development. The aim of the study was to evaluate serum salusin β levels in long-term acute lymphoblastic leukaemia survivors (ALLs) and Wilms’ tumour survivors (WTs) and compare these levels to established CVD risk factors.
Material and methods:
Thirty-seven ALLs and eleven WTs underwent physical examination and laboratory tests after an overnight fast at least 5 years after the end of oncological treatment. The laboratory tests included analysis of lipid profiles, serum glucose levels, renal parameters and salusin β levels.
Results:
The groups did not vary in age, time from the end of the treatment, number of obese persons, blood pressure, lipid profile, serum creatinine and glucose levels. The ALLs had greater weights and greater waist circumferences. The serum cystatin level was higher and the cystatin-based estimated glomerular filtration rate was lower in the WTs. Salusin β was higher in the WT group, but the result was not statistically significant.
Conclusions:
Acute lymphoblastic leukaemia survivors and WTs differ in terms of types of long-term side effects. Acute lymphoblastic leukaemia survivors more often develop obesity and metabolic problems, whereas WTs tend to develop renal disorders. Salusin β levels are associated with the level of LDL in ALLs and can indicate lipid disorders in patients with higher risk of obesity, suggesting that it could be a predictor of atherosclerosis. Further investigations are necessary to confirm this result. It is necessary to continue follow-up among adults who have been treated for childhood cancers to reveal long-term side effects such as cardiovascular disorders.
REFERENCES (26)
1.
Geenen MM, Bakker PJM, Kremer LCM, Kastelein JJP, Leeuwen FE van. Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukaemia and Wilms’ tumor treated with radiotherapy. Pediatr Blood Cance 2010; 55: 690-697.
2.
Robison LL, Green DM, Hudson M, et al. Long-term outcomes of adult survivors of childhood cancer. Cancer 2005; 104: 2557-2564.
3.
Tonorezos ES, Vega GL, Sklar CA, et al. Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia. Pediatr Blood Cancer 2012; 58: 31-36.
4.
Neville KA, Cohn RJ, Steinbeck KS, Johnston K, Walker JL. Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. J Clin Endocrinol Metab 2006; 91: 4401-4407.
5.
Zhou CH, Liu L, Liu L, et al. Salusin-β not salusin-α promotes vascular inflammation in ApoE-deficient mice via the I-κBα/NF-κB pathway. PLoS One 2014; 9: e91468.
6.
Sato K, Watanabe R, Itoh F, Shichiri M, Watanabe T. Salusins: potential use as a biomarker for atherosclerotic cardiovascular diseases. Int J Hypertens 2013; 2013: 965140.
7.
Sun HJ, Liu TY, Zhang F, et al. Salusin-β contributes to vascular remodeling associated with hypertension via promoting vascular smooth muscle cell proliferation and vascular fibrosis. Biochim Biophys Acta Mol Basis Dis 2015; 1852: 1709-1718.
8.
Niepolski L, Grzegorzewska AE. Salusins and adropin: new peptides potentially involved in lipid metabolism and atherosclerosis. Adv Med Sci 2016; 61: 282-287.
9.
Celik Ö, Yılmaz E, Celik N, et al. Salusins, newly identified regulators of hemodynamics and mitogenesis, increase in polycystic ovarian syndrome. Gynecol Endocrinol 2013; 29: 83-86.
10.
Report of the Second Task Force on Blood Pressure Control in Children – 1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 1987; 79: 1-25.
11.
KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Off J Int Soc Nephrol 2013; 3: 1-163.
12.
Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003; 18: 981-985.
13.
www.idf.org/e-library/consensus-statements/61-idf-consensus- defifition-of-metabolic-syndrome-in-children-and-adolescents.html (13.02.2021).
14.
Żurowska A. Rekomendacje Polskiego Towarzystwa Nefrologii Dziecięcej (PTNFD) dotyczące postępowania z dzieckiem z podwyższonym ciśnieniem tętniczym. www.ptnfd.org/zalecenia/ (13.02.2021).
15.
Litwin M, Niemirska A, Obrycki Ł, et al. Guidelines of the pediatric section of the polish society of hypertension on diagnosis and treatment of arterial hypertension in children and adolescents. Arter Hypertens 2018; 22: 45-73.
16.
Litwin M, Kułaga Z, Grajda A, Gurzkowska B, Napieralska E, Kułga K. Rozkłady wartości ciśnienia krwi w populacji referencyjnej dzieci i młodzieży w wieku szkolnym. Stand Med 2010; 7: 853-864.
17.
Litwin M, Kułaga Z, Różdżyńska A, et al. Siatki centylowe wysokości, masy ciała i wskaźniki masy ciała dzieci i młodzieży w Polsce – wyniki badania OLAF. Stand Med 2010; 7: 690-700.
18.
Krawczuk-Rybak M, Panasiuk A, Stachowicz-Stencel T, et al. Health status of Polish children and adolescents after cancer treatment. Eur J Pediatr 2018; 177: 437-447.
19.
Ociepa T, Bartnik M, Zielezińska K, Urasiński T. Prevalence and risk factors for arterial hypertension development in childhood acute lymphoblastic leukaemia survivors. J Pediatr Hematol Oncol 2019; 41: 175-180.
20.
Lu QB, Du Q, Wang HP, et al. Salusinβ mediates tubular cell apoptosis in acute kidney injury: Involvement of the PKC/ROS signaling pathway. Redox Biol 2020; 30: 101411.
21.
Kołakowska U, Olański W, Wasilewska A. Salusins in hypertension and related cardiovascular diseases. Curr Drug Metab 2016; 17: 827-833.
22.
Fujimoto K, Hayashi A, Kamata Y, et al. Circulating levels of human salusin-β, a potent hemodynamic and atherogenesis regulator. PLoS One 2013; 8: e76714.
23.
Kołakowska U, Kuroczycka-Saniutycz E, Wasilewska A, Olański W. Is the serum level of salusin-β associated with hypertension and atherosclerosis in the pediatric population? Pediatr Nephrol 2015; 30: 523-531.
24.
Kołakowska U, Kuroczycka-Saniutycz E, Olański W, Wasilewska A. Correlation of salusin beta with hs-CRP and ADMA in hypertensive children and adolescents. Curr Pharm Des 2018; 24: 3551-3557.
25.
Stefanowicz J, Owczuk R, Sierota D, Kaczorowska-Hać B, Balcerska A. Does antineoplasm treatment decrease the glomerular filtration rate in children? Kidney Blood Press Res 2009; 32: 194-199.
26.
Stefanowicz J, Kosiak M, Romanowicz G, Owczuk R, Adamkiewicz- Drożyńska E, Balcerska A. Glomerular filtration rate and prevalence of chronic kidney disease in Wilms’ tumour survivors. Pediatr Nephrol 2011; 26: 759-766.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
